Keith Katkin Sells 15,481 Shares of Emergent Biosolutions (NYSE:EBS) Stock

Emergent Biosolutions Inc. (NYSE:EBS) Director Keith Katkin sold 15,481 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $8.28, for a total transaction of $128,182.68. Following the completion of the sale, the director directly owned 96,294 shares of the company’s stock, valued at $797,314.32. The trade was a 13.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Up 0.4%

Shares of EBS stock traded up $0.04 on Monday, hitting $8.51. The stock had a trading volume of 839,196 shares, compared to its average volume of 878,575. The firm has a market capitalization of $439.23 million, a price-to-earnings ratio of -30.38 and a beta of 2.33. The stock’s 50 day moving average is $8.54 and its 200-day moving average is $10.30. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.08 and a current ratio of 4.29. Emergent Biosolutions Inc. has a 52-week low of $4.71 and a 52-week high of $14.06.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.46. The business had revenue of $156.10 million during the quarter, compared to the consensus estimate of $145.00 million. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. HC Wainwright decreased their target price on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Weiss Ratings downgraded shares of Emergent Biosolutions from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, April 27th. Finally, Wall Street Zen downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Emergent Biosolutions currently has a consensus rating of “Hold” and a consensus target price of $12.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in EBS. Millennium Management LLC grew its holdings in Emergent Biosolutions by 68.9% during the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after acquiring an additional 1,020,582 shares in the last quarter. Jain Global LLC acquired a new position in Emergent Biosolutions during the 3rd quarter worth $4,487,000. HRT Financial LP acquired a new position in Emergent Biosolutions during the 4th quarter worth $3,853,000. Dimensional Fund Advisors LP grew its holdings in Emergent Biosolutions by 15.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,140,340 shares of the biopharmaceutical company’s stock worth $18,878,000 after acquiring an additional 291,308 shares in the last quarter. Finally, Jump Financial LLC grew its holdings in Emergent Biosolutions by 468.4% during the 3rd quarter. Jump Financial LLC now owns 314,000 shares of the biopharmaceutical company’s stock worth $2,769,000 after acquiring an additional 258,757 shares in the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.